Trial Profile
Apixaban Versus Low-Molecular Weight Heparin For Thromboprophylaxis In Patients With Acute Spinal Cord Injury: A Pilot Study
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Feb 2020
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dalteparin sodium; Enoxaparin sodium
- Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
- Focus Therapeutic Use
- 18 Feb 2020 Status changed from recruiting to discontinued.
- 04 Apr 2018 Status changed from not yet recruiting to recruiting.
- 29 Jun 2017 New trial record